StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
OLMABullishCorporate Developmentsnews
High materiality8/10

Olema Advances Palazestrant; OPERA-01 Readout Expected 1Q2027; Bayer Collaboration

Aug 10, 2026, 4:04 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Key catalysts (1Q2027 OPERA-01 readout, Bayer collaboration) could re-rate probability of success and potential peak sales; a robust cash position supports execution and reduces near-term dilution risk.

AI summary

What happened, with direct paths to the underlying reporting

Olema reported Q2 2026 results with a completed OPERA-01 enrollment and guidance for first-quarter 2027 top-line palazestrant data. The company also highlighted encouraging OP-3136 Phase 1 signals and a Bayer collaboration to test OP-3136 with darolutamide in mCRPC. Cash runway remains robust at $461.1M, supporting late-stage trials and potential commercial preparation.

  • Completed enrollment in OPERA-01 Phase 3; top-line data expected Q1 2027.
  • OP-3136 Phase 1 data shown at ASCO 2026; Bayer collaboration announced.
  • Bayer collaboration to evaluate OP-3136 with darolutamide in mCRPC.
  • Q2 2026 cash and investments: $461.1M; net loss $63.2M.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event